Skip to main content

Advertisement

SpringerLink
Log in

Folgen der STICH-Studie für den klinischen Alltag

Indikationsstellung und chirurgische Therapie von Patienten mit ischämischer Kardiomyopathie

Consequences of the STICH trial for the clinical routine

Indications and surgical treatment of patients with ischemic cardiomyopathy

  • Im Brennpunkt
  • Published:
Zeitschrift für Herz-,Thorax- und Gefäßchirurgie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Menicanti L et al (2007) Surgical therapy for ischemic heart failure: single-center experience with surgical anterior ventricular restoration. J Thorac Cardiovasc Surg 134:433–441

    Article  PubMed  Google Scholar 

  2. Tulner SA et al (2006) Surgical ventricular restoration in patients with ischemic dilated cardiomyopathy: evaluation of systolic and diastolic ventricular function, wall stress, dyssynchrony, and mechanical efficiency by pressure-volume loops. J Thorac Cardiovasc Surg 132:610–620

    Article  PubMed  Google Scholar 

  3. Ten Brinke EA et al (2010) Long-term effects of surgical ventricular restoration with additional restrictive mitral annuloplasty and/or coronary artery bypass grafting on left ventricular function: six- months follow-up by pressure volume loops. J Thorac Cardiovasc Surg 140:1338–1344

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin I, SRH Zentralklinikum Suhl GmbH, Albert-Schweitzer-Str. 2, 98527, Suhl, Deutschland

    W. Haberbosch

Authors
  1. W. Haberbosch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Haberbosch.

Ethics declarations

Interessenkonflikt

W. Haberbosch gibt an, dass er Vortragshonorare von folgenden Firmen erhalten hat: MSD, Berlin-Chemie, Novartis, Sanofi und Amgen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haberbosch, W. Folgen der STICH-Studie für den klinischen Alltag. Z Herz- Thorax- Gefäßchir 31, 186–189 (2017). https://doi.org/10.1007/s00398-017-0139-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00398-017-0139-0

Search

Navigation